-
The Centers for Disease Control and Prevention recommends the following infection prevention measures for blood glucose monitoring and insulin administration.
-
A key advisory committee to the Centers for Disease Control and Prevention is expected to recommend that millions of diabetics be immunized against hepatitis B virus, a move that could finally halt the recurrent and deadly HBV outbreaks linked to needles and devices used in glucose monitoring in a variety of healthcare settings, Hospital Infection Control & Prevention has learned.
-
There have been recurrent warnings that the United States is facing an HIV clinician shortage that could lead to a critical setback in the fight against AIDS.
-
Medical schools, HIV organizations, foundations, and the federal government will need to work together to avert a crisis as the supply of HIV-trained physicians dwindles, experts say.
-
The global AIDS response is at "a scientific watershed" that includes both dramatic recent advances against HIV and the formidable challenge of extending the benefits to impoverished nations.
-
On May 23, 2011, the Food and Drug Administration approved telaprevir (Incivek®), an hepatitis C virus (HCV) protease inhibitor. Telaprevir is the second direct acting antiviral drug against the hepatitis C virus to be approved.
-
A landmark new CDC study dubbed TDF2 along with a separate trial released July 13, 2011 provide the first evidence that a daily oral dose of antiretroviral drugs used to treat HIV infection can reduce HIV acquisition among uninfected individuals exposed to the virus through heterosexual sex, the Centers for Disease Control & Prevention reports.
-
At least one HIV physician is not waiting for a federal or foundation-based solution to her personal HIV doctor shortage problem. Instead she has tackled the problem by "growing" her own HIV clinician.
-
Researchers and clinicians are achieving game-changing results that are revolutionizing HIV prevention, care and treatment, Michel Sidibé, Executive Director of the Joint United Nations Programme on HIV/AIDS (UNAIDS) said recently in Rome at the IAS 2011 conference.
-
Herrera and colleagues reviewed the use of Interferon-ã release assays (IGRAs) for the diagnosis of latent tuberculosis infection (LTBI). Interferon-ã is released by CD4 cells when infected with Mycobacterium tuberculosis (MTB), and IGRAs measure Interferon-ã response in blood.
